Biomerica Inc (BMRA) stock
BMRANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 15, 2026Score 8/3055% below fair value
$1.10+0.01 (+0.92%)
Close on Nov 19, 2026Market cap $5.06MP/E –Yield –
Biomerica net income
Net income is the profit left for shareholders after every expense, interest and tax.
Biomerica's net income for the twelve months ending Aug 31, 2026 was -$5.01M. For fiscal 2026 it was -$3.78M. The highest annual figure on record is $548.44K in fiscal 2012.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | -$3.78M | – |
| FY2025 | May 31, 2025 | -$4.97M | – |
| FY2024 | May 31, 2024 | -$5.98M | – |
| FY2023 | May 31, 2023 | -$7.14M | – |
| FY2022 | May 31, 2022 | -$4.53M | – |
| FY2021 | May 31, 2021 | -$7.45M | – |
| FY2020 | May 31, 2020 | -$2.68M | – |
| FY2019 | May 31, 2019 | -$2.39M | – |
| FY2018 | May 31, 2018 | -$1.47M | – |
| FY2017 | May 31, 2017 | -$908.56K | – |
| FY2016 | May 31, 2016 | -$1.50M | – |
| FY2015 | May 31, 2015 | -$331.41K | – |
| FY2014 | May 31, 2014 | -$215.66K | -140.2% |
| FY2013 | May 31, 2013 | $536.96K | -2.1% |
| FY2012 | May 31, 2012 | $548.44K | +248.3% |
| FY2011 | May 31, 2011 | $157.45K | – |
Quarterly net income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | -$1.23M | -61700.0% |
| Q4 FY2026CQ2 2026 | May 31, 2026 | -$1.15M | – |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | -$1.31M | – |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | -$1.32M | – |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | $2.00K | – |
| Q4 FY2025CQ2 2025 | May 31, 2025 | -$1.54M | – |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | -$1.16M | – |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | -$950.00K | – |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | -$1.32M | – |
| Q4 FY2024CQ2 2024 | May 31, 2024 | -$1.42M | – |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | -$1.92M | – |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | -$1.51M | – |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | -$1.13M | – |
| Q4 FY2023CQ2 2023 | May 31, 2023 | -$1.79M | – |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | -$1.65M | – |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | -$1.63M | – |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | -$2.07M | – |
| Q4 FY2022CQ2 2022 | May 31, 2022 | -$1.76M | – |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | -$104.17K | – |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | -$1.13M | – |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | -$1.54M | – |
| Q4 FY2021CQ2 2021 | May 31, 2021 | -$1.71M | – |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | -$2.12M | – |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | -$1.72M | – |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | -$1.89M | – |
| Q4 FY2020CQ2 2020 | May 31, 2020 | -$824.69K | – |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | -$860.93K | – |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | -$485.26K | – |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | -$506.30K | – |
| Q4 FY2019CQ2 2019 | May 31, 2019 | -$785.33K | – |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | -$678.75K | – |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | -$477.24K | – |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | -$451.74K | – |
| Q4 FY2018CQ2 2018 | May 31, 2018 | -$667.62K | – |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | -$322.49K | – |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | -$268.66K | – |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | -$207.06K | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | -$345.82K | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | -$304.14K | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | -$202.89K | – |
See a number that looks wrong?